Debbie Rigby takes a look at the latest in research news
This overview of systematic reviews concluded that evidence regarding the effectiveness of paracetamol is insufficient for drawing firm conclusions. Evidence for its efficacy in four conditions (nee or hip osteoarthritis, after craniotomy, tension‐type headache, perineal pain soon after childbirth) was moderate to strong. There was strong evidence that paracetamol is not effective for reducing acute low back pain.
MJA, first published 30 March 2021.
This narrative review suggests that pharmacists can provide evidence-based recommendations concerning the indications, dosing, monitoring, and adverse effects of vitamin D supplements. There is evidence for vitamin D supplementation in individuals aged 75 years or older and in those with problems associated with mobility, gait, or balance. There is insufficient evidence to support vitamin D supplementation in the prevention of cardiovascular disease, cancer, asthma, chronic obstructive pulmonary disease exacerbations, new-onset type 2 diabetes, infectious lung diseases, cognitive dysfunction, Alzheimer disease, and depression, or in prenatal use.
J Am Pharm Assoc 2021;S1544-3191(21)00070-4.
In this cluster-randomised controlled trial, multicomponent interventions including provider- and patient-focused components attempted to reduce the use of high-risk anticholinergics in older adults receiving primary care. The intervention resulted in no significant differences in either the number of discontinue orders for anticholinergics or proportion of the population using anticholinergics following the intervention. The authors suggested that improving nudges or a policy‐focused component may be necessary to reduce use of high‐risk medications.
Journal of the American Geriatrics Society, first published 26 March 2021.
A systematic review and meta-analysis of 5 RCTs involving 5526 patients shows that colchicine treatment may be effective to reduce major adverse cardiovascular events in patients undergoing PCI. Colchicine significantly reduced major adverse cardiovascular events but had no impact on mortality, myocardial infarction, serious adverse events or restenosis.
Am J Emerg Med 2021;46:121-125.